In SF3B1-mutant MDS, several possible mechanistic explanations for disease have led to proposed disease targets [158], In MDS, Luspatercept has been shown to have clinical promise in low-risk MDS with ringed sideroblasts in the MEDALIST trial, and low-risk MDS in the COMMANDS trials, which led to FDA approval [159,160,161,162]. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.